Tags : Locally Advanced

Merck’s Keytruda Receives the NMPA’s Approval as a 2L Treatment

Shots: The approval is based on P-III KEYNOTE-181 study assessing Keytruda vs CT in previously treated patients with recurrent or metastatic ESCC whose tumors expressed PD-L1 (CPS ≥10) and  data from an extension of the global study in Chinese patients Results: Median OS (10.3 vs 6.7mos.), in Chinese patients: median OS (12.0 vs 5.4mos.). With […]Read More

Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in

Shots: The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not progress after completion of 1L Pt-chemotherapy The study resulted in improvement in OS with consistent safety results and will be shared with the US FDA […]Read More

Seattle Genetics and Astellas Report Acceptance of BLA for Enfortumab

Shots: The BLA submission is based on EV-201 P-II clinical study assessing Enfortumab Vedotin in patients with LA/m- urothelial cancer prior treated with PD-1/L1 inhibitor, including patients treated/not treated with platinum-containing CT ineligible for cisplatin The US FDA has granted Priority Review to the BLA which is a milestone toward offering a new therapy to […]Read More